ViroMed Completes Trial for Cardiovascular Disease Treatment

ViroMed has announced that the final injections for patients enrolled in a Phase I clinical trial in China for VM202, the company’s proprietary DNA medicine for various types of cardiovascular disease (CVD), have been completed.

The clinical trial, which consists of 21 patients being treated with VM202-PAD, a form of VM202 for the treatment of peripheral artery disease (PAD), had been ongoing at Xuanwu Hospital, Capital University of Medical Sciences in Beijing. The Phase I trial will officially be completed once the final safety and efficacy results have been submitted to the State Food and Drug Administration (SFDA), after a three month observation period following the final injections.